What BPC-157 is
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide - a 15-amino acid sequence - derived from a protein found in gastric juice. The parent protein, BPC (body protection compound), was identified in human gastric juice and found to have cytoprotective properties in the gastric mucosa. The 157 designation refers to the specific fragment isolated and studied.
BPC-157 is not a naturally occurring circulating peptide in the way that insulin or GLP-1 is. It is a fragment derived from a gastric protein, studied primarily as an experimental compound in animal research.
The animal research landscape
The substantial majority of BPC-157 research has been conducted by one research group based in Zagreb, Croatia, led by Predrag Sikiric. This group has published extensively on BPC-157's effects in rat models across a wide range of contexts: gastric ulcers, tendon and ligament healing, muscle injury, bone healing, and neurological injury models.
In rat studies, BPC-157 has been reported to accelerate healing of transected tendons, promote angiogenesis (blood vessel formation) at injury sites, reduce markers of oxidative stress in tissue, and show cytoprotective effects in the gut.
The mechanistic proposed explanation centres on BPC-157's interaction with the nitric oxide (NO) system and growth hormone (GH) receptor signalling. Some studies suggest BPC-157 may upregulate expression of growth hormone receptors in tendon fibroblasts.
What the limitations are
Several important caveats apply to the BPC-157 literature:
Single-group dominance: The vast majority of BPC-157 papers come from the Sikiric group. Independent replication by unaffiliated research groups is limited, which is an important check in science that is largely absent here.
Animal models only: There are no published randomised controlled trials of BPC-157 in humans. Effects observed in rat tendon healing or rat gastric injury models may not translate directly to human physiology, dosing, or safety.
Publication bias: Research in peptides with commercial interest can be subject to selective publication. Negative results are less likely to be published.
Mechanism is incompletely characterised: Despite the volume of papers, the primary receptor through which BPC-157 produces its effects has not been definitively identified.
What this means for interpreting BPC-157 research
The existing animal literature suggests BPC-157 has measurable biological effects in rodent models across several tissue types. This is sufficient to justify continued research and constitutes legitimate scientific interest. It is not sufficient to draw conclusions about efficacy or safety in humans, dosing in humans, or the equivalence of effects seen in animal wound-healing models to any human condition.
The gap between "active in rats" and "demonstrated to work in humans" is the gap that controlled human trials are designed to close. BPC-157 has not crossed that gap in the published literature as of 2025.
References: Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011. Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol. 2011. Gwyer D et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019.
What BPC-157 is
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide - a 15-amino acid sequence - derived from a protein found in gastric juice. The parent protein, BPC (body protection compound), was identified in human gastric juice and found to have cytoprotective properties in the gastric mucosa. The 157 designation refers to the specific fragment isolated and studied.
BPC-157 is not a naturally occurring circulating peptide in the way that insulin or GLP-1 is. It is a fragment derived from a gastric protein, studied primarily as an experimental compound in animal research.
The animal research landscape
The substantial majority of BPC-157 research has been conducted by one research group based in Zagreb, Croatia, led by Predrag Sikiric. This group has published extensively on BPC-157's effects in rat models across a wide range of contexts: gastric ulcers, tendon and ligament healing, muscle injury, bone healing, and neurological injury models.
In rat studies, BPC-157 has been reported to accelerate healing of transected tendons, promote angiogenesis (blood vessel formation) at injury sites, reduce markers of oxidative stress in tissue, and show cytoprotective effects in the gut.
The mechanistic proposed explanation centres on BPC-157's interaction with the nitric oxide (NO) system and growth hormone (GH) receptor signalling. Some studies suggest BPC-157 may upregulate expression of growth hormone receptors in tendon fibroblasts.
What the limitations are
Several important caveats apply to the BPC-157 literature:
Single-group dominance: The vast majority of BPC-157 papers come from the Sikiric group. Independent replication by unaffiliated research groups is limited, which is an important check in science that is largely absent here.
Animal models only: There are no published randomised controlled trials of BPC-157 in humans. Effects observed in rat tendon healing or rat gastric injury models may not translate directly to human physiology, dosing, or safety.
Publication bias: Research in peptides with commercial interest can be subject to selective publication. Negative results are less likely to be published.
Mechanism is incompletely characterised: Despite the volume of papers, the primary receptor through which BPC-157 produces its effects has not been definitively identified.
What this means for interpreting BPC-157 research
The existing animal literature suggests BPC-157 has measurable biological effects in rodent models across several tissue types. This is sufficient to justify continued research and constitutes legitimate scientific interest. It is not sufficient to draw conclusions about efficacy or safety in humans, dosing in humans, or the equivalence of effects seen in animal wound-healing models to any human condition.
The gap between "active in rats" and "demonstrated to work in humans" is the gap that controlled human trials are designed to close. BPC-157 has not crossed that gap in the published literature as of 2025.
References: Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011. Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol. 2011. Gwyer D et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019.
